EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Risk of therapy related leukemia and preleukemia after hodgkin's disease relation to age cumulative dose of alkylating agents and time from chemotherapy



Risk of therapy related leukemia and preleukemia after hodgkin's disease relation to age cumulative dose of alkylating agents and time from chemotherapy



Lancet 2(8550): 83-88



391 patients treated intensively for Hodgkin's disease were followed for up to 15 years to evaluate the risk of therapy-related acute non-lymphocytic leukaemia (t-ANLL) and preleukaemia. Only two independent factors, patient age and cumulative dose of alkylating agents, were related to the risk of t-ANLL. The hazard rate of t-ANLL was roughly proportional to the square of patients age and to the total cumulative dose of alkylating agents. In 320 patients treated with alkylating agents the cumulative risk of t-ANLL increased steadily from 1 year after the start of treatment and reached 13.cntdot.0% (SE 3.cntdot.0) at 10 years after which time there were no further cases. Calculated from cessation of therapy with alkylating agents, however, the cumulative risk curve increased steeply during the first 1-2 years then gradually levelled out and no new cases were observed beyond 7 years. With a 15-year follow-up the general risk of solid tumours was not increased.

(PDF 0-2 workdays service: $29.90)

Accession: 006345707

Download citation: RISBibTeXText

PMID: 2885581



Related references

Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. Journal of Clinical Oncology 12(5): 1063-1073, 1994

Point mutation of the ras protooncogenes and chromosome aberrations in acute nonlymphocytic leukemia and preleukemia related to therapy with alkylating agents. Cancer Research 48(7): 1812-1817, 1988

The role of marrow transplantation in the treatment of preleukemia therapy related preleukemia and acute leukemia evolving from preleukemia. Gale, R P And R Champlin (Ed ) Ucla (University Of California-Los Angeles) Symposia on Molecular And Cellular Biology New Series, Vol 53 Progress in Bone Marrow Transplantation; Fourth International Symposium, Keystone, Colorado, Usa, April 13-18, 1986 Xxxv+1012p Alan R Liss, Inc : New York, New York, Usa Illus 103-120, 1987

Venocclusive disease of the liver after high-dose chemotherapy with alkylating agents Incidence, outcome, and risk factors. Hepatology 26(4 PART 2): 149A, 1997

Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non hodgkins lymphomas comparison with results obtained in patients treated for hodgkins disease and ovarian carcinoma with other alkylating agents. Annals of Internal Medicine 103(2): 195-200, 1985

Risk of therapy related myelodysplasia acute non lymphocytic leukemia and bladder cancer following therapy with alkylating agents the finsen institute denmark experience. Journal of Cancer Research & Clinical Oncology 116(SUPPL PART 2): 983, 1990

Risk of secondary acute leukemia and preleukemia after Hodgkin's disease: the Institut Gustave-Roussy experience. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres Dans les Recherches sur le Cancer 117: 270-283, 1989

Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 109(3): 905-909, 2006

Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 109(3): 905-909, 2007

Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Annals of Oncology 13(3): 450-459, 2002

High-dose therapy with autologous transplantation induce a high rate of primary ovarian failure A study of 80 women treated with alkylating agents for Hodgkin and non Hodgkin lymphomas. Blood 96(11 Part 1): 403a, November 16, 2000

High risk of therapy-related leukemia and preleukemia after therapy with prednimustine, methotrexate, 5-fluorouracil, mitoxantrone, and tamoxifen for advanced breast cancer. Cancer 65(11): 2460-2464, 1990

Are alkylating agents a necessary component in the therapy of Hodgkin's disease. Leukemia & Lymphoma 10 Suppl: 91-97, 1993